Afamitresgene Autoleucel: The First Engineered T-Cell Therapy for Synovial Sarcoma

Table of Contents

1. Synovial Sarcoma in Brief
2. What the Therapy Is
3. How the Treatment Is Given
4. Who the Label Covers
5. The Trial Results
6. Side Effects in the Label
7. How It Differs From CAR-T Therapies
8. What Is Not Known
9. Key Research Papers
10. Connections
11. Featured Videos

Synovial Sarcoma in Brief

Sarcomas are cancers of the body's connective tissues: muscle, fat, nerves, blood vessels, bone and cartilage. Synovial sarcoma is one type of soft-tissue sarcoma. A clinical review from Canada puts it at 5–10% of all soft-tissue sarcomas, and notes that it is diagnosed at a younger age than most other sarcomas. A 2023 review estimates about 1,000 new cases a year in the United States.

What defines synovial sarcoma is a genetic accident inside the tumour cells: a swap of material between the X chromosome and chromosome 18, written t(X;18). The swap fuses two genes, SS18 and SSX, into a single abnormal gene that drives the cancer. The Canadian review calls this fusion the hallmark of the disease, and testing for it is part of how the diagnosis is confirmed alongside imaging and a biopsy.

When the tumour can be removed, wide surgery is the standard treatment, with radiation added for larger and deeper tumours. The same review describes the role of chemotherapy as still debated. Once the cancer has spread or cannot be removed, the standard treatment described in the 2023 review is chemotherapy built around an anthracycline drug such as doxorubicin. That review reports that advanced synovial sarcoma responds to chemotherapy more often than other soft-tissue sarcomas, but that median survival at this stage is under 18 months. This is the group of patients the new therapy was tested in.

What the Therapy Is

T cells are the white blood cells that recognise and kill infected or abnormal cells. Each T cell carries a T-cell receptor (TCR), a surface molecule that fits one specific target. The target is not a whole protein. Cells constantly chop up their own proteins and display small fragments on their surface in a holder called the human leukocyte antigen (HLA) molecule, the same tissue-type system that is matched before organ transplants. A T-cell receptor recognises one fragment sitting in one kind of human leukocyte antigen holder.

The prescribing information describes afamitresgene autoleucel as the patient's own CD4 and CD8 T cells that have been given, by a disabled virus called a self-inactivating lentiviral vector, the gene for an "affinity-enhanced" T-cell receptor. That receptor recognises a fragment of a protein called melanoma-associated antigen A4 (MAGE-A4) when the fragment is held in the HLA-A*02 type of human leukocyte antigen. The label explains that melanoma-associated antigen A4 is an intracellular "cancer-testis antigen": a protein made inside cells, with restricted expression in normal adult tissues, that is expressed in synovial sarcoma. Despite its name, it is not limited to melanoma.

When the engineered T cells meet a tumour cell displaying that fragment in that holder, the label states, the cells multiply, release signalling molecules called cytokines, and kill the tumour cell. In the phase 1 trial, exploratory analyses found the infused cells inside tumours, a mechanism driven by the cytokine interferon-gamma, and signs that the patient's wider immune system was drawn into the response.

How common the target is in synovial sarcoma depends on the study. In a Japanese series of 82 patients with surgically treated high-grade soft-tissue sarcoma, 52.9% of the synovial sarcomas stained positive for melanoma-associated antigen A4, and 70.6% were positive for it or for a second cancer-testis antigen, NY-ESO-1. In the same series none of the myxoid liposarcomas stained positive for melanoma-associated antigen A4.

How the Treatment Is Given

The prescribing information describes a sequence of steps that takes several weeks:

• Testing. In the trial, each patient had high-resolution tissue typing at a central laboratory, and a tumour sample was stained for melanoma-associated antigen A4 at a central laboratory.
• Collection. White blood cells are collected from the patient's blood by leukapheresis, a machine process that separates them out and returns the rest of the blood.
• Manufacture. The T cells are enriched, given the receptor gene, multiplied, washed, frozen in a solution containing 5% dimethyl sulfoxide, and shipped back in liquid-nitrogen vapour at −130°C or colder. In the first trial group the label reports a manufacturing or delivery failure in 8% of patients (4 of 52). While waiting, 16 of the 44 treated patients (36%) received other cancer treatment, called bridging therapy.
• Lymphodepletion. Before the infusion, patients received two chemotherapy drugs, fludarabine for 4 days and cyclophosphamide for 3 days, starting a week before. This lowers the patient's existing white blood cells so the infused cells have room to expand.
• Infusion. The cells are given once, as a drip into a vein. In the first trial group the median dose was 8 billion receptor-carrying T cells, within a range of about 2.7 to 10 billion.
• Monitoring. The 2024 label instructs treating centres to watch patients at the healthcare facility for at least 7 days after the infusion, and to continue watching for cytokine release syndrome and nerve-system effects for at least 4 weeks.

Not every patient who starts the process receives the cells. Of the 52 patients with synovial sarcoma who underwent cell collection in the first trial group, 44 received the infusion. The label lists the reasons for the others as death (3), loss of eligibility before the chemotherapy (3), withdrawal by the patient (1) and investigator decision (1).

Who the Label Covers

The August 2024 label covers adults with synovial sarcoma that cannot be removed by surgery or has spread, who have already received chemotherapy, and who meet two test-based conditions:

• Tissue type. They carry one of four versions of the HLA-A*02 tissue type, written HLA-A*02:01P, -A*02:02P, -A*02:03P or -A*02:06P. In the trial, 96% of treated patients carried HLA-A*02:01P.
• Tumour protein. Their tumour expresses melanoma-associated antigen A4, as shown by a test approved or cleared by the FDA for this purpose (a companion diagnostic).

The label lists one contraindication: the therapy is not to be used in people who carry HLA-A*02:05P on either copy of the gene. The trial also excluded people taking systemic corticosteroids for 14 days or more before cell collection and people who had received a stem-cell transplant from a donor.

The 2024 approval was an accelerated approval, granted on the response rate and how long responses lasted. The 2024 label states that continued approval "may be contingent upon verification and description of clinical benefit in a confirmatory trial." The current version of the prescribing information, revised in June 2026, lists the accelerated-approval statement as removed and extends the indication to patients 12 years of age and older. It states that safety and effectiveness have not been established below 12 years of age.

The Trial Results

The phase 1 trial

The first trial in people, published in 2023, was a dose-finding study in 38 patients with nine kinds of solid tumour expressing melanoma-associated antigen A4. Its main purpose was safety. Tumours shrank by a defined amount (a partial response) in 24% of patients overall: 7 of 16 people with synovial sarcoma (44%), compared with 2 of 22 people with all the other cancers combined (9%). No patient had a complete response. In synovial sarcoma the median duration of response was 28.1 weeks. The authors note that the small size of the trial limits the conclusions.

SPEARHEAD-1

The approval rests on SPEARHEAD-1, a phase 2 trial run at 23 sites in Canada, the United States and Europe. It was open-label and single-arm: every patient received the therapy and there was no comparison group. The main group (cohort 1) enrolled people aged 16 to 75 with advanced synovial sarcoma or myxoid round cell liposarcoma whose tumours expressed melanoma-associated antigen A4 and who had had at least one earlier chemotherapy containing an anthracycline or ifosfamide. The patients had been heavily treated before, with a median of three earlier lines of treatment.

The 2024 Lancet report covers 52 patients (44 with synovial sarcoma and 8 with myxoid round cell liposarcoma), with a median follow-up of 32.6 months. Tumours were measured by a masked independent review committee using a standard scale (RECIST version 1.1). The response rate was 39% (17 of 44) in synovial sarcoma and 25% (2 of 8) in myxoid round cell liposarcoma. No treatment-related deaths occurred.

The figures in the FDA label

The FDA's figures for the 44 treated patients with synovial sarcoma differ slightly from the published paper, because, as the FDA's approval summary explains, the agency identified issues with data quality and study conduct during its review and asked for an independent re-review of the scans. The FDA based its decision on that re-review. The 2024 label reports:

• Overall response rate: 43.2% (95% confidence interval 28.4–59.0), meaning tumours shrank by at least the RECIST threshold in about 4 in 10 treated patients.
• Complete response: 2 patients (4.5%), in whom the measured tumours disappeared. Partial response: 17 patients (38.6%).
• Median duration of response: 6.0 months (95% confidence interval 4.6 months to not reached), with individual responses lasting from 1.9 months to more than 36.1 months. Among responders, 45.6% were still responding at 6 months and 39.0% at 12 months.
• Time to response: a median of 4.9 weeks after the infusion.

The FDA approval summary gives a median follow-up of 21.9 months for these figures. The June 2026 label pools all three SPEARHEAD-1 cohorts: of 137 treated patients with synovial sarcoma, 43.8% responded and 3.6% had a complete response, with a median duration of response of 5.3 months; 31.9% of responders were still responding at 12 months and at 24 months. Counting all 171 patients who had cells collected, including those who never received an infusion, the response rate was 35.1%.

A 2026 review of the evidence by French sarcoma specialists describes responses lasting more than 11 months in synovial sarcoma and calls the therapy a proof of concept for engineered T-cell receptor therapies in solid tumours.

Side Effects in the Label

The boxed warning: cytokine release syndrome

The label carries a boxed warning, the FDA's most prominent safety warning, for cytokine release syndrome. This is a body-wide inflammatory reaction that happens when large numbers of activated immune cells release cytokines at once. The label states it "may be severe or life-threatening." In the 44 treated patients in the 2024 label, it occurred in 75%, and 2% had grade 3 or higher (severe). It began a median of 2 days after the infusion (range 1 to 5 days) and lasted a median of 3 days. The most common signs were fever (97% of those affected), a fast heartbeat (52%), low blood pressure (30%), nausea or vomiting (21%) and headache (15%). More than half (55%) were treated with tocilizumab, a drug that blocks the inflammatory signal interleukin-6. The label lists fever, chills, fast or irregular heartbeat, low blood pressure, light-headedness, shortness of breath, nausea, vomiting, diarrhoea and headache as signs for which patients are told to seek immediate medical attention.

Low blood counts

The most frequent severe effects in the trial were low blood counts, which the 2026 review attributes to the lymphodepleting chemotherapy. The Lancet report lists low lymphocytes in 96%, low neutrophils (the infection-fighting white cells) in 85% and low total white cells in 81% of the 52 patients at grade 3 or worse. The 2024 label reports that some patients still had severe low counts four weeks after infusion: neutropenia in 11%, anaemia in 9% and thrombocytopenia (low platelets) in 5%. For these patients, median recovery took between 6.3 and 9.3 weeks, depending on the blood count.

Infections and other effects

• Infections occurred in 32% of patients, and 14% were grade 3 or higher. The label reports febrile neutropenia (fever with very low neutrophils) and reactivation of dormant viruses after treatment.
• Nerve-system effects (immune effector cell-associated neurotoxicity syndrome) occurred in one patient (2%), grade 1, with mild changes in mental state. Because of possible dizziness and fainting, the 2024 label tells prescribers to advise patients not to drive or operate dangerous machinery for at least 4 weeks.
• Serious adverse reactions of any kind occurred in 52% of patients, most often cytokine release syndrome (9%) and fluid around the lungs (7%). The most common effects overall included nausea (66%), vomiting (36%), fatigue (34%) and fever (32%).
• Secondary cancers. The label states that new cancers may develop after treatment. The FDA approval summary reports one patient with an Epstein-Barr virus-positive lymphoproliferative disease.
• Allergic reactions, including anaphylaxis, may occur because of the dimethyl sulfoxide in the frozen product.
• False-positive HIV tests. The virus used to deliver the gene shares short stretches of genetic material with HIV, so some HIV nucleic-acid tests may read falsely positive.

The phase 1 trial reported grade 3 or higher blood-count problems in all 38 patients. Pregnancy was not studied: the 2024 label states there are no data in pregnant women and no data on fertility.

How It Differs From CAR-T Therapies

Afamitresgene autoleucel belongs to the same broad family as chimeric antigen receptor (CAR) T-cell therapy: both take a patient's own T cells, add a gene in a laboratory, multiply the cells and infuse them back after lymphodepleting chemotherapy. Both can cause cytokine release syndrome. The difference lies in what the engineered cells recognise.

• What they target. A chimeric antigen receptor is an artificial receptor built partly from an antibody. It recognises whole proteins standing on the outside of the cell. An engineered T-cell receptor recognises a small fragment of a protein that the cell has displayed in its human leukocyte antigen holder, which means the protein can come from inside the cell. A 2021 review explains that this opens a larger pool of possible targets, which matters for solid tumours, where suitable surface targets are harder to find. The target of afamitresgene autoleucel, melanoma-associated antigen A4, is an intracellular protein.
• Tissue-type restriction. Because a T-cell receptor reads a fragment only in one kind of human leukocyte antigen holder, the therapy works only in people with a matching tissue type. Chimeric antigen receptor T cells do not depend on the patient's tissue type. Reviews from 2025 and 2026 list this restriction as one of the main limits of engineered T-cell receptor therapy.
• Where they are approved. The 2021 review notes that chimeric antigen receptor T-cell products were approved for blood cancers. The FDA approval summary describes afamitresgene autoleucel as the first FDA-approved T-cell receptor gene therapy, and it is approved for a solid tumour.

A 2025 review of cell therapies in sarcoma reports that most engineered T-cell receptor trials in sarcoma target melanoma-associated antigen A4 or NY-ESO-1. It notes that a second product, letetresgene autoleucel, received a breakthrough designation for myxoid/round cell liposarcoma, and that chimeric antigen receptor trials in sarcoma mainly aim at surface proteins such as B7H3, GD2, FGFR4 and HER2. Tumour-infiltrating lymphocyte therapy, which grows T cells taken from the tumour itself, is also under study.

What Is Not Known

• Whether people live longer. The approval was based on how many tumours shrank and how long the shrinkage lasted. SPEARHEAD-1 had no comparison group, so it cannot show how the therapy compares with chemotherapy or other treatments on survival. The 2024 label tied continued approval to verification of clinical benefit in a confirmatory trial.
• How solid the response figures are. The FDA approval summary records data-quality and study-conduct issues that led to an independent re-review of the scans, and the published and FDA response rates differ (39% and 43.2% for the same 44 patients).
• Why most patients do not respond. Fewer than half of treated patients responded, and the median response lasted about six months. Reviews name the tumour's surrounding environment, which can switch off T cells, and differences in how much target protein tumours carry as open problems.
• Who can be reached. Only people with the matching tissue types and a tumour that tests positive are eligible, and in the Japanese series only about half of synovial sarcomas carried the target protein. The 2026 review lists the tissue-type restriction, manufacturing delays, cost and equitable access as unresolved.
• Long-term effects. The label lists secondary cancers as a possible risk, and data on pregnancy and fertility are lacking. The published SPEARHEAD-1 report had a median follow-up of 32.6 months.
• Children and older adults. The 2024 label covered adults only. The 2026 label extends coverage to age 12 and older on the basis of 6 adolescents in the trial and extrapolation from adults; children younger than 12 were not studied, and too few people aged 65 or older took part to tell whether they respond differently.

Decisions about cancer treatment belong with the oncology team treating the patient. This page reports what the label and trials state.

Key Research Papers

1. Barnett KK, Johnson AR, Das A, Lee CJ, Wang C, Wang X, et al. FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy. Clin Cancer Res. 2025;31(15):3112-3117. PubMed PMID: 40423661
2. D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403(10435):1460-1471. PubMed PMID: 38554725
3. Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, et al. Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2023;29(1):104-114. PubMed PMID: 36624315
4. Dupont M, Dufresne A, Brahmi M, Romeo C, Blay JY. An evaluation of afamitresgene autoleucel for the treatment of advanced synovial sarcoma and myxoid round cell liposarcoma. Expert Rev Anticancer Ther. 2026;26(6):661-670. PubMed PMID: 41472526
5. Keam SJ. Afamitresgene Autoleucel: First Approval. Mol Diagn Ther. 2024;28(6):861-866. PubMed PMID: 39404764
6. Gazendam AM, Popovic S, Munir S, Parasu N, Wilson D, Ghert M. Synovial Sarcoma: A Clinical Review. Curr Oncol. 2021;28(3):1909-1920. PubMed PMID: 34069748
7. Fuchs JR, Schulte BC, Fuchs JW, Agulnik M. Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma. Front Oncol. 2023;13:1123464. PubMed PMID: 36761952
8. Kakimoto T, Matsumine A, Kageyama S, Asanuma K, Matsubara T, Nakamura T, et al. Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma. Oncol Lett. 2019;17(4):3937-3943. PubMed PMID: 30881511
9. Kucharczyk M, Hatipoglu E, Jones RL, Huang PH. Adoptive T-Cell Therapy in Sarcomas. Curr Oncol Rep. 2025;27(10):1131-1143. PubMed PMID: 40810970
10. Greenbaum U, Dumbrava EI, Biter AB, Haymaker CL, Hong DS. Engineered T-cell Receptor T Cells for Cancer Immunotherapy. Cancer Immunol Res. 2021;9(11):1252-1261. PubMed PMID: 34728535
11. Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol. 2022;11(1):38. PubMed PMID: 35725570

Label figures are taken from the U.S. prescribing information for afamitresgene autoleucel: the first version (August 2024, SPEARHEAD-1 cohort 1, 44 patients) and the revised version (June 2026, cohorts 1–3, 137 patients), as published on DailyMed.

PubMed Topic Searches

1. afamitresgene autoleucel
2. MAGE-A4 synovial sarcoma
3. TCR T-cell therapy sarcoma
4. synovial sarcoma SS18-SSX
5. cytokine release syndrome T-cell receptor therapy

Connections

• Drugs — every drug page on the site
• Sarcoma — the family of connective-tissue cancers that includes synovial sarcoma
• Oncology — the cancer pages on the site
• Ewing Sarcoma — another fusion-gene sarcoma of young people
• Tocilizumab — the interleukin-6 blocker used for cytokine release syndrome
• Dimethyl Sulfoxide — the freezing agent in the cell product
• Non-Hodgkin Lymphoma — a blood cancer treated with chimeric antigen receptor T cells
• Allison & Honjo — checkpoint immunotherapy, another way of turning T cells on cancer

Featured Videos